Research

Hormonal

Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces ad libitum energy intake, suppresses appetite, and improves control of eating in adults with obesity, leading to clinically meaningful weight loss, without evidence of delayed gastric emptying at steady state.

Take 2.4 mg of subcutaneous semaglutide once weekly. Start with the lowest dose (0.25 mg) and escalate every 4 weeks as directed to minimize side effects. Expect a significant reduction in hunger, food cravings, and overall calorie intake, leading to weight loss without needing to manually restrict calories.

GoodSupportsHIGH confidence
In adults with obesity, once-weekly s.c. semaglutide 2.4 mg suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake and body weight versus placebo. There was no evidence of delayed gastric emptying at week 20, assessed indirectly via paracetamol absorption.
Martin Friedrichsen et al. · Diabetes Obesity and Metabolism · 2020

Why this rating

Randomized, double-blind, placebo-controlled trial with a robust sample size (n=72) and clear statistical significance for secondary endpoints.

Source

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

Martin Friedrichsen et al. · Diabetes Obesity and Metabolism · 2020

DOI 10.1111/dom.14280

rct · n=72Cited 372×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →